International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.
作者信息
Mancuso Michelangelo, McFarland Robert, Klopstock Thomas, Hirano Michio
机构信息
Department of Experimental and Clinical Medicine, Neurological Institute, University of Pisa, Italy.
Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Department of Physiology and Functional Genomics NE1 3BZ, Newcastle University, Newcastle upon Tyne, UK.
出版信息
Neuromuscul Disord. 2017 Dec;27(12):1126-1137. doi: 10.1016/j.nmd.2017.08.006. Epub 2017 Sep 8.
Abstract
摘要
相似文献
1
International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.国际研讨会：儿童及成人原发性线粒体肌病的疗效评估指标与临床试验准备情况。共识性建议。2016年11月16 - 18日，意大利罗马
Neuromuscul Disord. 2017 Dec;27(12):1126-1137. doi: 10.1016/j.nmd.2017.08.006. Epub 2017 Sep 8.
2
280th ENMC International Workshop: The ERN EURO-NMD mitochondrial diseases working group; diagnostic criteria and outcome measures in primary mitochondrial myopathies. Hoofddorp, the Netherlands, 22-24 November 2024.第280届ENMC国际研讨会：ERN欧洲神经肌肉疾病线粒体疾病工作组；原发性线粒体肌病的诊断标准和结局指标。荷兰霍夫多普，2024年11月22日至24日。
Neuromuscul Disord. 2025 May;50:105340. doi: 10.1016/j.nmd.2025.105340. Epub 2025 Mar 22.
3
Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi-based international workshop.儿童线粒体疾病的结局测量指标：基于德尔菲法的国际研讨会对未来研究的共识建议。
J Inherit Metab Dis. 2018 Nov;41(6):1267-1273. doi: 10.1007/s10545-018-0229-5. Epub 2018 Jul 19.
4
1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15-16 November 2016, Evry, France.第一届肌聚糖病临床试验准备国际研讨会，2016年11月15 - 16日，法国埃夫里
Neuromuscul Disord. 2017 Jul;27(7):683-692. doi: 10.1016/j.nmd.2017.02.011. Epub 2017 Mar 3.
5
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop.确立血液透析试验的核心心血管结局指标：国际共识研讨会报告。
Am J Kidney Dis. 2020 Jul;76(1):109-120. doi: 10.1053/j.ajkd.2020.01.022. Epub 2020 May 12.
6
International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA.国际研讨会：确保雷特综合征的疗效指标适用于临床试验需要什么？2023年6月7日，美国纳什维尔
Trials. 2024 Dec 21;25(1):845. doi: 10.1186/s13063-024-08678-6.
7
213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.第213届ENMC国际研讨会：特发性炎性肌病的疗效评估指标及临床试验准备情况，荷兰海姆斯凯尔克，2015年9月18 - 20日
Neuromuscul Disord. 2016 Aug;26(8):523-34. doi: 10.1016/j.nmd.2016.05.014. Epub 2016 May 27.
8
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations.制定用于疼痛临床试验的患者报告结局测量指标：IMMPACT 建议
Pain. 2006 Dec 5;125(3):208-215. doi: 10.1016/j.pain.2006.09.028. Epub 2006 Oct 25.
9
Research priorities for non-pharmacological therapies for common musculoskeletal problems: nationally and internationally agreed recommendations.常见肌肉骨骼问题的非药物治疗研究重点：国家和国际商定的建议
BMC Musculoskelet Disord. 2009 Jan 9;10:3. doi: 10.1186/1471-2474-10-3.
10
Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert Guidance.共济失调临床结局评估和登记发展的共识建议：共济失调全球倡议（AGI）工作组专家指南。
Cerebellum. 2024 Jun;23(3):924-930. doi: 10.1007/s12311-023-01547-z. Epub 2023 Apr 5.
引用本文的文献
1
The profound implications of mitochondrial myopathy on activities of daily living: an observational qualitative study of standardized structured and semi-structured patient interviews.线粒体肌病对日常生活活动的深远影响：一项对标准化结构化和半结构化患者访谈的观察性定性研究。
Ther Adv Chronic Dis. 2025 Jul 25;16:20406223251344763. doi: 10.1177/20406223251344763. eCollection 2025.
2
Open-label pilot study using hydroxytyrosol as dietary supplements in patients with mitochondrial diseases.一项开放标签的试点研究，在患有线粒体疾病的患者中使用羟基酪醇作为膳食补充剂。
Orphanet J Rare Dis. 2025 Jun 6;20(1):283. doi: 10.1186/s13023-025-03795-0.
3
The most bothersome symptoms in neuromuscular diseases: the ERN EURO NMD Survey.神经肌肉疾病中最困扰人的症状：ERN欧洲神经肌肉疾病调查
Orphanet J Rare Dis. 2025 May 8;20(1):221. doi: 10.1186/s13023-025-03742-z.
4
GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy.GDF15中和可改善线粒体肌病小鼠模型中的肌肉萎缩和运动不耐受。
J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13715. doi: 10.1002/jcsm.13715.
5
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.依罗培南肽治疗原发性线粒体肌病患者的基因型特异性效果：MMPOWER-3 试验的事后分析。
Orphanet J Rare Dis. 2024 Nov 21;19(1):431. doi: 10.1186/s13023-024-03421-5.
6
Resolving Phenotypic Variability in Mitochondrial Diseases: Preliminary Findings of a Proteomic Approach.解析线粒体疾病中的表型异质性：一种蛋白质组学方法的初步研究结果。
Int J Mol Sci. 2024 Oct 5;25(19):10731. doi: 10.3390/ijms251910731.
7
Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.原发性线粒体疾病患者癫痫发作的管理：InterERNs 线粒体工作组的共识声明。
Eur J Neurol. 2024 Jul;31(7):e16275. doi: 10.1111/ene.16275. Epub 2024 Apr 4.
8
A clinical approach to diagnosis and management of mitochondrial myopathies.线粒体肌病的临床诊断与治疗方法。
Neurotherapeutics. 2024 Jan;21(1):e00304. doi: 10.1016/j.neurot.2023.11.001. Epub 2023 Dec 19.
9
Characterization of Fatigue in Primary Mitochondrial Myopathies: Findings From a Qualitative Interview Study.原发性线粒体肌病中疲劳的特征：一项定性访谈研究的结果
Neurol Clin Pract. 2024 Feb;14(1):e200229. doi: 10.1212/CPJ.0000000000200229. Epub 2023 Dec 22.
10
Mitochondrial myopathy without extraocular muscle involvement: a unique clinicopathologic profile.线粒体肌病伴眼外肌不受累：一种独特的临床病理特征。
J Neurol. 2024 Feb;271(2):864-876. doi: 10.1007/s00415-023-12005-5. Epub 2023 Oct 17.
本文引用的文献
1
Quantification of gait in mitochondrial m.3243A > G patients: a validation study.线粒体m.3243A > G患者步态的量化：一项验证研究。
Orphanet J Rare Dis. 2017 May 15;12(1):91. doi: 10.1186/s13023-017-0644-y.
2
Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke project.线粒体疾病临床研究的通用数据元素：美国国立神经疾病和中风研究所项目
J Inherit Metab Dis. 2017 May;40(3):403-414. doi: 10.1007/s10545-017-0035-5. Epub 2017 Mar 16.
3
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.修订版脊髓性肌萎缩症哈默史密斯量表：一种脊髓性肌萎缩症特异性临床结局评估工具。
PLoS One. 2017 Feb 21;12(2):e0172346. doi: 10.1371/journal.pone.0172346. eCollection 2017.
4
Domains of Daily Physical Activity in Children with Mitochondrial Disease: A 3D Accelerometry Approach.线粒体疾病患儿日常身体活动的领域：一种三维加速度计方法。
JIMD Rep. 2017;36:7-17. doi: 10.1007/8904_2016_35. Epub 2017 Jan 17.
5
The 6-min mastication test: a unique test to assess endurance of continuous chewing, normal values, reliability, reproducibility and usability in patients with mitochondrial disease.6分钟咀嚼试验：一项评估线粒体疾病患者持续咀嚼耐力、正常值、可靠性、可重复性及实用性的独特试验。
J Oral Rehabil. 2017 Mar;44(3):155-162. doi: 10.1111/joor.12481. Epub 2017 Jan 30.
6
Toward a therapy for mitochondrial disease.迈向线粒体疾病的治疗方法。
Biochem Soc Trans. 2016 Oct 15;44(5):1483-1490. doi: 10.1042/BST20160085.
7
Dynamic P-MRSI using spiral spectroscopic imaging can map mitochondrial capacity in muscles of the human calf during plantar flexion exercise at 7 T.使用螺旋光谱成像的动态磷磁共振波谱成像（P-MRSI）能够在7T磁场下对人体小腿肌肉在跖屈运动期间的线粒体功能进行成像。
NMR Biomed. 2016 Dec;29(12):1825-1834. doi: 10.1002/nbm.3662. Epub 2016 Nov 8.
8
Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease.线粒体疾病中临床医生评定的结局指标的初步评估
J Neuromuscul Dis. 2015 Jun 4;2(2):151-155. doi: 10.3233/JND-140061.
9
FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.成纤维细胞生长因子21是线粒体翻译和线粒体DNA维持障碍的生物标志物。
Neurology. 2016 Nov 29;87(22):2290-2299. doi: 10.1212/WNL.0000000000003374. Epub 2016 Oct 28.
10
Mitochondrial diseases.线粒体疾病。
Nat Rev Dis Primers. 2016 Oct 20;2:16080. doi: 10.1038/nrdp.2016.80.
Zotero 插件